Southeast Asia Demonstrates Considerable Scope for Sale of Targeted Therapies for Breast Cancer Treatment

Published Date : May 22, 2017

ALBANY, New York, May 22, 2017: Already a multi-billion dollar industry, the breast cancer therapeutics market in Southeast Asia is expected to surpass its current value considerably by 2022. With Southeast Asia witnessing a rapid incidence of breast cancer, nations are compelled to focus on research and development of novel therapeutics. has announced the addition of a market study delving into prospects for the breast cancer therapeutics market in Southeast Asia. The report is titled, “Breast Cancer T herapeutics In Southeast Asia Markets To 2022 - Increasing Prevalence And Usage Of Premium Targeted Therapies To Drive The Market,” and is available for sale on the company website.

According to WHO, breast cancer has become the second most common type of disease affecting millions globally. While the U.S., EU, and Australia are known to report a high prevalence of the ailment, the number of patients ailing for the same has increased in Southeast Asia as well. Currently the Southeast breast cancer therapeutics market comprises hormonal therapies chemotherapies, and other targeted therapies. Herceptin is a gold standard monoclonal antibody, which is commonly prescribed for treating HER2-assessed countries. However, its use in Southeast Asian countries has remained restricted owing to limitations in the diagnosis of HER2 status and persisting affordability issues.

In addition, Southeast Asian countries are witnessing the high prevalence of unmet need in treatment options for triple negative breast cancer. These countries have continued depending on chemotherapies for the treatment, which again are limited in terms of toxicity and efficacy. The demand for effective treatment is therefore quite high in Southeast Asia. However, the market has witnessed increased uptake of various premium branded drugs and targeted therapies in countries such as South Korea, Taiwan, and Singapore.

For Sample Copy, click here:

Premium therapies such as Perjeta and Kadcyla are yet to be approved in Thailand, Indonesia, Malaysia, and Vietnam. Despite lower scope for sales of these drugs, they will continue holding a substantial share in Southeast Asia breast cancer therapeutics market due to their superior quality, high efficacy, and high price. Also in a few years, when these drugs are approved in the aforementioned nations, their share in the overall market will increase further.

Besides Kadcyla and Perjeta, the Southeast Asia breast cancer therapeutics market comprises CDK inhibitors such as Ibrance and tyrosine kinase inhibitors such as Tykerb. Growth in the sales of these drugs will therefore up Southeast Asia’s share in the overall breast cancer therapeutics market. The report presents a thorough reports of various factors supporting the market’s expansion in Southeast Asia. Policies and behavior of governments toward these targeted therapies are studied for individual Southeast Asian countries. Besides this, the report also presents insights into factors leading to high demand for a particular drug from a given country.

The report also presents a detailed reports of the marketed drugs and those, which are in pipeline. It is therefore compiled to help stakeholders gain a better perspective of the Southeast Asia breast cancer therapeutics market. Toward the end, the report studies the competition prevailing in the market by profiling some of the leading players operating therein. Their individual market share is calculated in the report as well.

To order report Call Toll Free: 866-997-4948 or send an email on